Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sensyne Health confirms benefits in study

21 Jan 2020 07:00

RNS Number : 3869A
Sensyne Health PLC
21 January 2020
 

 

Sensyne Health study confirms benefits of blood anticoagulants for heart failure patients

Research offers key insight into disease affecting more than one million adults in the UK

 

 

Oxford, U.K. 21 January 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the British Clinical AI technology company, analysed anonymised, routinely collected data from nearly half a million NHS patients as part of a study seeking to identify if there are benefits to the use of blood thinning agents (anticoagulants) for all heart failure patients.

 

Heart failure is a highly heterogeneous disease which affects more than one million UK adults, is one of the most common causes of hospital admission and is responsible for 10,000 deaths a year. It severely compromises a patient's quality of life, and treating it comes with significant costs, amounting to 1-2% of the NHS' annual budget (c. £625 million). Heart failure is associated with the development of blood clots which can break away and block blood vessels in the brain, causing strokes. NICE guidelines have recommended anticoagulants for heart failure patients who have an irregular heartbeat, which increases the likelihood of blood clots forming. However, this treatment is also associated with increased bleeding risks in the stomach and brain.

 

Currently, two different classes of anticoagulant are commonly used. Warfarin, an off-patent drug developed in the 1940s, and a newer group of medicines known as NOACs developed over the last decade. Sensyne compared the anonymised data over three years of heart failure patients with no record of anti-coagulant prescription (the 'control arm') with that of patients prescribed either warfarin or NOACs.

 

The benefit of anticoagulants in patients with an irregular heartbeat is well documented. The data in this study also suggested a small but statistically significant survival benefit for heart failure patients without an irregular heart on anticoagulants, but further analysis is required to confirm if the difference is clinically relevant, and if so which subgroups of patients would benefit the most. The analysis also suggests that there may be relevant differences, not only between the use of warfarin compared to NOACs, but also between the NOACs currently in use. This is an early observation worthy of further exploration.

 

The expense and complexity of randomised controlled trials means that they tend to be focused on highly defined, specific groups of patients which do not necessarily reflect the diversity observed in day to day practice. By contrast, Sensyne's in silico analysis of the real-world data in electronic patient records, offers the enticing potential of a faster, more representative and cost-effective alternative.

 

These findings are interesting in their own right, but the combination of these standard, statistical approaches with the application of Sensyne Health's machine learning patient stratification algorithm

that identifies different subgroups of heart failure patients is where the opportunities lie for enhanced analysis, insights and clinical understanding.

 

Sensyne Health, a leading company in this field, has developed a unique partnership relationship with NHS Trusts to enable it to analyse ethically sourced, anonymised patient data to undertake such research.

 

Sir Bruce Keogh KBE, Interim Chairman of Sensyne Health said: "This work demonstrates the value of Sensyne's partnership with the NHS which allows rapid and cost-effective analysis of therapeutic efficacy outside the confines of randomised clinical trials in a way that reflects the reality of routine clinical practice. The Sensyne / NHS partnership offers the prospect of new insights leading to iterative improvements in healthcare."

 

-ENDS-

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer

Lorimer Headley, Chief Financial Officer

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

sensynehealth@consilium-comms.com

 

 

About Sensyne Health 

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com www.sensynehealth.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAEAAFEAEXEEAA
Date   Source Headline
5th Feb 20217:00 amRNSManagement appointments
3rd Feb 20217:00 amRNSLaunch of AI algorithm for patient management
21st Jan 20217:00 amRNSSensyne Health Interim Results
20th Jan 20217:00 amRNSSensyne signs SRA with Wolverhampton NHS Trust
19th Jan 202111:06 amRNSHolding(s) in Company
15th Jan 20214:41 pmRNSSecond Price Monitoring Extn
15th Jan 20214:36 pmRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSSensyne launches MagnifEye smartphone app
13th Jan 20212:58 pmRNSHolding(s) in Company
11th Jan 20217:00 amRNSNotice of Interim Results
7th Jan 20215:12 pmRNSHolding(s) in Company
7th Jan 20215:09 pmRNSHolding(s) in Company
4th Jan 20213:06 pmRNSResult of General Meeting & Fundraising Completion
4th Jan 20213:05 pmRNSResult of Open Offer
18th Dec 20207:00 amRNSSensyne Health appoints Non-Executive Director
15th Dec 20207:00 amRNSLaunch of First Digital Health Product in the US
14th Dec 20207:00 amRNSPublication of Circular and General Meeting Notice
9th Dec 202011:06 amRNSSecond Price Monitoring Extn
9th Dec 202011:01 amRNSPrice Monitoring Extension
9th Dec 20209:05 amRNSSecond Price Monitoring Extn
9th Dec 20209:00 amRNSPrice Monitoring Extension
9th Dec 20207:00 amRNSSuccessful completion of Fundraise
8th Dec 20205:36 pmRNSProposed Fundraising
25th Nov 20207:00 amRNSSensyne Health Agreement with Hampshire NHS Trust
17th Nov 20202:05 pmRNSSecond Price Monitoring Extn
17th Nov 20202:00 pmRNSPrice Monitoring Extension
16th Nov 20207:02 amRNSSensyne Health achieves 5 million patient target
16th Nov 20207:00 amRNSSensyne Health Agreement with Somerset NHS Trust
13th Nov 20207:00 amRNSSensyne Health appoints President, North America
2nd Nov 20207:00 amRNSCOVID-19 testing study at University of Oxford
30th Oct 20204:33 pmRNSResult of AGM
28th Oct 20207:00 amRNSSensyne Health Agreement with Microsoft
26th Oct 20207:00 amRNSSensyne Health Agreement with Milton Keynes UH
23rd Oct 20207:00 amRNSSensyne Health agreement with Bristol Myers Squibb
6th Oct 20207:00 amRNSAnnual Report and Accounts and Notice of AGM
5th Oct 20204:40 pmRNSSecond Price Monitoring Extn
5th Oct 20204:35 pmRNSPrice Monitoring Extension
1st Oct 20206:07 pmRNSHolding(s) in Company
1st Oct 20202:00 pmRNSAgreement with NHS Greater Glasgow and Clyde
30th Sep 20201:12 pmRNSCollaboration with the University of Oxford
30th Sep 20207:01 amRNSSensyne Health Long Term Incentive Plan
30th Sep 20207:00 amRNSSensyne Health Full Year Results
29th Sep 202011:55 amRNSHolding(s) in Company
29th Sep 20209:46 amRNSHolding(s) in Company
23rd Sep 20207:00 amRNSNotice of Full Year Results
10th Sep 20207:00 amRNSSensyne Health appoints Chief Operating Officer
3rd Sep 20207:00 amRNSUK launch of ‘SENSE’ in partnership with Microsoft
20th Aug 20209:05 amRNSSecond Price Monitoring Extn
20th Aug 20209:00 amRNSPrice Monitoring Extension
19th Aug 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.